In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
[38] The androgen insensitivity syndrome, formerly known as testicular feminization, is caused by a mutation in the androgen receptor gene on the X chromosome (locus: Xq11Xq12)
Non-negotiable if reflux wakes you up at night
Side effect profiles shift depending on when you inject
Research interest in PT-141 has included melanocortin receptor signaling, receptor selectivity, neurobiological pathways, inflammatory response models, vascular response models, and related peptide structure-activity relationships